The Samsung-developed drug will be marketed to healthcare providers by Merck & Co.'s U.S. sales team and will be sold for about a 35% discount off of Remicade's current list price. "Samsung Releases Lower-Cost Alternative to Johnson & Johnson's Drug Remicade ," at 8:21 a.m. ET, incorrectly stated that the drug will be sold for about 35% of Remicade's price. in the second paragraph.

 

(END) Dow Jones Newswires

July 24, 2017 09:15 ET (13:15 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Samsung Electronics (PK) (USOTC:SSNHZ)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Samsung Electronics (PK) Charts.
Samsung Electronics (PK) (USOTC:SSNHZ)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Samsung Electronics (PK) Charts.